Skip to main content

Latest from Medicine Matters oncology

Latest headlines

20-10-2023 | Prostate cancer | News

Enzalutamide use supported for biochemically recurrent prostate cancer

Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

Man receiving radiotherapy

06-10-2023 | Prostate cancer | News

Add-on SBRT improves outcomes of men with oligometastatic CRPC

Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.

04-10-2023 | Adverse events | News

High incidence of alpelisib‐associated hyperglycemia in routine care

A retrospective analysis has found a significantly higher incidence of hyperglycemia among breast cancer patients treated with alpelisib in standard care than on clinical trials.

29-09-2023 | Adverse events | News

Trial adds to evidence for risk-based thromboprophylaxis in people with cancer

Findings from the TARGET-TP trial support a risk-directed approach to thromboprophylaxis in ambulatory patients with gastrointestinal or lung cancer receiving systemic anticancer treatment.

22-09-2023 | KRAS inhibitors | News

Novel KRAS inhibitor elicits ‘durable responses’ in KRAS G12C mutation-positive tumors

The novel KRAS inhibitor divarasib has shown promise in previously treated patients with advanced solid tumors harboring a KRAS G12C mutation.

13-09-2023 | Immunotherapy | News

Cutaneous irAEs tied to improved survival after ICI treatment

A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.

Feature content

20-04-2023 | Urothelial cancer | At a glance | Article

At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

A summary of the key trial publications on the use of PD-1 pathway and CTLA-4 inhibitors alone or in combination in the second-line or later treatment of locally advanced and metastatic urothelial carcinoma.

This independent article was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ARROW points the way for RET fusion-positive NSCLC treatment

ARROW points the way for RET fusion-positive NSCLC treatment

Stephen Liu outlines the ARROW study design and findings and discusses the impact of pralsetinib on the care of patients with treatment-naïve and previously treated NSCLC positive for a RET fusion

RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC

RET fusion-positive NSCLC: Delivering targeted treatment

Stephen Liu leads Melina Marmarelis and Vivek Subbiah in a discussion on the care of patients with RET fusion-positive NSCLC in light of the ARROW trial of pralsetinib.